AbbVie Inc. (NYSE:ABBV) may not have been too far off the mark when it claimed a Humira biosimilar is unlikely to reach markets before at least 2022.
http://www.bidnessetc.com/61315-amgen-loses-out-on-humira-abbvie-growth-plans-intact/
- Forums
- ASX - By Stock
- UNS
- Abbvie Humira
Abbvie Humira
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)